30 results on '"Karunanidhi, Anuradha"'
Search Results
2. Heptanoic and medium branched-chain fatty acids as anaplerotic treatment for medium chain acyl-CoA dehydrogenase deficiency
- Author
-
Karunanidhi, Anuradha, Basu, Shakuntala, Zhao, Xue-Jun, D'Annibale, Olivia, Van't Land, Clinton, Vockley, Jerry, and Mohsen, Al-Walid
- Published
- 2023
- Full Text
- View/download PDF
3. Mitochondrial dysfunction associated with TANGO2 deficiency
- Author
-
Heiman, Paige, Mohsen, Al-Walid, Karunanidhi, Anuradha, St Croix, Claudette, Watkins, Simon, Koppes, Erik, Haas, Richard, Vockley, Jerry, and Ghaloul-Gonzalez, Lina
- Published
- 2022
- Full Text
- View/download PDF
4. Reticular Dysgenesis and Mitochondriopathy Induced by Adenylate Kinase 2 Deficiency with Atypical Presentation
- Author
-
Ghaloul-Gonzalez, Lina, Mohsen, Al-Walid, Karunanidhi, Anuradha, Seminotti, Bianca, Chong, Hey, Madan-Khetarpal, Suneeta, Sebastian, Jessica, Vockley, Catherine Walsh, Reyes-Múgica, Miguel, Vander Lugt, Mark T., and Vockley, Jerry
- Published
- 2019
- Full Text
- View/download PDF
5. Investigating the link of ACAD10 deficiency to type 2 diabetes mellitus
- Author
-
Bloom, Kaitlyn, Mohsen, Al-Walid, Karunanidhi, Anuradha, El Demellawy, Dina, Reyes-Múgica, Miguel, Wang, Yudong, Ghaloul-Gonzalez, Lina, Otsubo, Chikara, Tobita, Kimi, Muzumdar, Radhika, Gong, Zhenwei, Tas, Emir, Basu, Shrabani, Chen, Jie, Bennett, Michael, Hoppel, Charles, and Vockley, Jerry
- Published
- 2018
- Full Text
- View/download PDF
6. ETHE1 and MOCS1 deficiencies: Disruption of mitochondrial bioenergetics, dynamics, redox homeostasis and endoplasmic reticulum-mitochondria crosstalk in patient fibroblasts
- Author
-
Grings, Mateus, Seminotti, Bianca, Karunanidhi, Anuradha, Ghaloul-Gonzalez, Lina, Mohsen, Al-Walid, Wipf, Peter, Palmfeldt, Johan, Vockley, Jerry, and Leipnitz, Guilhian
- Published
- 2019
- Full Text
- View/download PDF
7. Messenger RNA rescues medium-chain acyl-CoA dehydrogenase deficiency in fibroblasts from patients and a murine model.
- Author
-
Zhao, Xue-Jun, Mohsen, Ai-Walid, Mihalik, Stephanie, Solo, Keaton, Basu, Shakuntala, Aliu, Ermal, Shi, Huifang, Kochersberger, Catherine, Karunanidhi, Anuradha, Land, Clinton Van't, Coughlan, Kimberly A, Siddiqui, Summar, Rice, Lisa M, Hillier, Shawn, Guadagnin, Eleonora, DeAntonis, Christine, Giangrande, Paloma H, Martini, Paolo G V, and Vockley, Jerry
- Published
- 2023
- Full Text
- View/download PDF
8. ELAMIPRETIDE RESTORES MITOCHONDRIAL FUNCTION IN TRIFUNCTIONAL PROTEIN DEFICIENCY MICE AND HUMAN FIBROBLASTS
- Author
-
Neto, Eduardo Vieira, Wang, Yudong, Basu, Shakuntala, Zhao, Xuejun, Karunanidhi, Anuradha, and Vockley, Jerry
- Published
- 2023
- Full Text
- View/download PDF
9. ANAPLEROTIC COMPOUNDS IMPROVE O2CONSUMPTION AND RESTORE SUCCINYLLYSINE ANTIGENIC SIGNAL IN LONG-CHAIN FATTY ACID OXIDATION DEFICIENT CELLS
- Author
-
Seminotti, Bianca, Karunanidhi, Anuradha, Vockley, Jerry, and Mohsen, Al-Walid
- Published
- 2023
- Full Text
- View/download PDF
10. EFFECT OF TRIHEPTANOIN AND MEDIUM BRANCHED-CHAIN FATTY ACIDS ON LYSINE SUCCINYLATION IN HUMAN MCAD DEFICIENT FIBROBLAST CELLS AND MURINE KO MODEL
- Author
-
Karunanidhi, Anuradha, Basu, Shakuntala, Zhao, Xuejun, Van't land, Clinton, Vockley, Jerry, and Mohsen, Al-Walid
- Published
- 2023
- Full Text
- View/download PDF
11. Complex I assembly function and fatty acid oxidation enzyme activity of ACAD9 both contribute to disease severity in ACAD9 deficiency
- Author
-
Schiff, Manuel, Haberberger, Birgit, Xia, Chuanwu, Mohsen, Al-Walid, Goetzman, Eric S., Wang, Yudong, Uppala, Radha, Zhang, Yuxun, Karunanidhi, Anuradha, Prabhu, Dolly, Alharbi, Hana, Prochownik, Edward V., Haack, Tobias, Häberle, Johannes, Munnich, Arnold, Rötig, Agnes, Taylor, Robert W., Nicholls, Robert D., Kim, Jung-Ja, Prokisch, Holger, and Vockley, Jerry
- Published
- 2015
- Full Text
- View/download PDF
12. Treatment of VLCAD-Deficient Patient Fibroblasts with Peroxisome Proliferator-Activated Receptor δ Agonist Improves Cellular Bioenergetics.
- Author
-
D'Annibale, Olivia M., Phua, Yu Leng, Van't Land, Clinton, Karunanidhi, Anuradha, Dorenbaum, Alejandro, Mohsen, Al-Walid, and Vockley, Jerry
- Subjects
PEROXISOME proliferator-activated receptors ,BIOENERGETICS ,ADOLESCENCE ,FIBROBLASTS ,GENE expression ,MISSENSE mutation - Abstract
Background: Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency is an autosomal recessive disease that prevents the body from utilizing long-chain fatty acids for energy, most needed during stress and fasting. Symptoms can appear from infancy through childhood and adolescence or early adulthood, and include hypoglycemia, recurrent rhabdomyolysis, myopathy, hepatopathy, and cardiomyopathy. REN001 is a peroxisome-proliferator-activated receptor delta (PPARδ) agonist that modulates the expression of the genes coding for fatty acid β-oxidation enzymes and proteins involved in oxidative phosphorylation. Here, we assessed the effect of REN001 on VLCAD-deficient patient fibroblasts. Methods: VLCAD-deficient patient and control fibroblasts were treated with REN001. Cells were harvested for gene expression analysis, protein content, VLCAD enzyme activity, cellular bioenergetics, and ATP production. Results: VLCAD-deficient cell lines responded differently to REN001 based on genotype. All cells had statistically significant increases in ACADVL gene expression. Small increases in VLCAD protein and enzyme activity were observed and were cell-line- and dose-dependent. Even with these small increases, cellular bioenergetics improved in all cell lines in the presence of REN001, as demonstrated by the oxygen consumption rate and ATP production. VLCAD-deficient cell lines containing missense mutations responded better to REN001 treatment than one containing a duplication mutation in ACADVL. Discussion: Treating VLCAD-deficient fibroblasts with the REN001 PPARδ agonist results in an increase in VLCAD protein and enzyme activity, and a decrease in cellular stress. These results establish REN001 as a potential therapy for VLCADD as enhanced expression may provide a therapeutic increase in total VLCAD activity, but suggest the need for mutation-specific treatment augmented by other treatment measures. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Medium branched chain fatty acids improve the profile of tricarboxylic acid cycle intermediates in mitochondrial fatty acid β‐oxidation deficient cells: A comparative study.
- Author
-
Karunanidhi, Anuradha, Van't Land, Clinton, Rajasundaram, Dhivyaa, Grings, Mateus, Vockley, Jerry, and Mohsen, Al‐Walid
- Abstract
Inherited errors of mitochondrial fatty acid β‐oxidation (FAO) are life threatening, even with optimum care. FAO is the major source of energy for heart and is critical for skeletal muscles especially during physiologic stress. Clinical trials revealed that triheptanoin (commercially known as Dojolvi; C7G), improved heart function and decreased hypoglycemia in long chain FAO disorders, but other symptoms including rhabdomyolysis persisted, suggesting suboptimal tissue distribution/utilization of heptanoic acid (C7) conjugates and/or rapid liver breakdown. In this study, medium branched chain fatty acids were tested as potential anaplerotic treatments in fibroblasts from patients deficient in very long chain acyl‐CoA dehydrogenase (VLCAD), long chain 3‐hydroxyacyl‐CoA dehydrogenase (LCHAD), trifunctional protein (TFP), and carnitine palmitoyltransferase II (CPT II). Cells were cultured to near confluency and treated with C7, 2,6‐dimethylheptanoic acid (dMC7), 6‐amino‐2,4‐dimethylheptanoic acid (AdMC7), or 4,8‐dimethylnonanoic acid (dMC9) for 72 h and targeted metabolomics performed. The profile of TCA cycle intermediates was improved in cells treated with these branched chain fatty acids compared with C7. Intracellular propionate was higher in AdMC7 treated cells compared with C7 in VLCAD, LCHAD, and TFP deficient cell lines. With AdMC7 treatment, succinate was higher in CPT II and VLCAD deficient cells, compared with C7. Malate and glutamate were consistently higher in AdMC7 treated VLCAD, LCHAD, TFP, and CPT II deficient cells compared with the C7 treatment. The results provide the impetus to further evaluate and consider branched chain fatty acids as viable anaplerotic therapy for fatty acid oxidation disorders and other diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Medium-chain acyl-CoA dehydrogenase substrate binding site: A pharmacophore target for MCAD mutant chaperone therapy.
- Author
-
Mohsen, Al-Walid, Karunanidhi, Anuradha, and Vockley, Jerry
- Subjects
- *
PHARMACOPHORE , *BINDING sites , *ACYL coenzyme A - Published
- 2024
- Full Text
- View/download PDF
15. ACAD10 protein expression and Neurobehavioral assessment of Acad10-deficient mice.
- Author
-
Bloom, Kaitlyn, Karunanidhi, Anuradha, Tobita, Kimimasa, Hoppel, Charles, Thiels, Edda, Peet, Eloise, Wang, Yudong, Basu, Shrabani, and Vockley, Jerry
- Subjects
- *
PROTEIN expression , *FATTY acid oxidation , *WEIGHT gain , *PEROXISOMES ,BRAIN metabolism - Abstract
Acyl-CoA dehydrogenase 10 (Acad10)-deficient mice develop impaired glucose tolerance, peripheral insulin resistance, and abnormal weight gain. In addition, they exhibit biochemical features of deficiencies of fatty acid oxidation, such as accumulation of metabolites consistent with abnormal mitochondrial energy metabolism and fasting induced rhabdomyolysis. ACAD10 has significant expression in mouse brain, unlike other acyl-CoA dehydrogenases (ACADs) involved in fatty acid oxidation. The presence of ACAD10 in human tissues was determined using immunohistochemical staining. To characterize the effect of ACAD10 deficiency on the brain, micro-MRI and neurobehavioral evaluations were performed. Acad10-deficient mouse behavior was examined using open field testing and DigiGait analysis for changes in general activity as well as indices of gait, respectively. ACAD10 protein was shown to colocalize to mitochondria and peroxisomes in lung, muscle, kidney, and pancreas human tissue. Acad10-deficient mice demonstrated subtle behavioral abnormalities, which included reduced activity and increased time in the arena perimeter in the open field test. Mutant animals exhibited brake and propulsion metrics similar to those of control animals, which indicates normal balance, stability of gait, and the absence of significant motor impairment. The lack of evidence for motor impairment combined with avoidance of the center of an open field arena and reduced vertical and horizontal exploration are consistent with a phenotype characterized by elevated anxiety. These results implicate ACAD10 function in normal mouse behavior, which suggests a novel role for ACAD10 in brain metabolism. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Mitochondrial energetics is impaired in very long-chain acyl-CoA dehydrogenase deficiency and can be rescued by treatment with mitochondria-targeted electron scavengers.
- Author
-
Seminotti, Bianca, Leipnitz, Guilhian, Karunanidhi, Anuradha, Kochersperger, Catherine, Roginskaya, Vera Y, Basu, Shrabani, Wang, Yudong, Wipf, Peter, Houten, Bennett Van, Mohsen, Al-Walid, and Vockley, Jerry
- Published
- 2019
- Full Text
- View/download PDF
17. Response of Bone Subjected to Optimized High Dose Irradiation.
- Author
-
BURGESS, H. WILSON, MACKRELL, JAMES, TOMS, DEREK, KARUNANIDHI, ANURADHA, VAIDYA, SWAROOPA, HOLLINGER, JEFFREY O., GRIEB, TERI A., and BERTENSHAW, GREG P.
- Subjects
HOMOGRAFTS ,OSSEOINTEGRATION ,GUIDED bone regeneration ,RADIATION-protective agents ,MUSCULOSKELETAL system ,SURGERY - Abstract
Allograft tissues are used in over one million musculoskeletal procedures per year. Consequently, it is crucial tissue banks use procedures to militate against allograft associated bacterial and viral infections. Recent studies have identified an important pathogen inactivation technology for musculoskeletal allografts that utilizes high-dose gamma irradiation (50 kGy) under controlled conditions. A total dose of 50 kGy assures that the current standard for medical devices for a microbial sterility assurance level of 10
-6 is met. Furthermore, the pathogen inactivation technology results in a greater than four log inactivation of enveloped and nonenveloped viruses. Efficacious clinical outcome from musculoskeletal allografts exposed to this innovative sterilization procedure will require that there is no performance decrement in the allograft's biological properties. Therefore, to validate this objective, we executed a study focusing on remodeling and osteoconduction of bone allografts treated with a high dose of gamma irradiation (50 kGy), radioprotectants and well-defined operating parameters of temperature and water content. A rabbit calvarial model was used to test the hypothesis that remodeling and osteoconduction of allogeneic bone treated with the new pathogen inactivation technology would be equivalent to nontreated allogeneic bone. Results indicated treated bone allografts were comparable to nontreated allografts. We conclude, therefore, that based on this outcome and other reports, that high doses of gamma irradiation under optimized conditions designed to reduce free radical damage to tissue will provide safer allografts. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
18. Preclinical Toxicology Studies of Recombinant Human Platelet-Derived Growth Factor-BB Either Alone or in Combination with Beta-Tricalcium Phosphate and Type I Collagen.
- Author
-
Young, Conan S., Bradica, Gino, Hart, Charlie E., Karunanidhi, Anuradha, Street, Reva M., Schutte, Lyndsey, and Hollinger, Jeffrey O.
- Subjects
RECOMBINANT human insulin ,GROWTH factors ,DNA synthesis ,CELL division ,ATHEROSCLEROSIS treatment ,EXPERIMENTAL toxicology ,SOFT tissue injuries ,PHYSIOLOGY - Abstract
Human platelet-derived growth factor-BB (hPDGF-BB) is a basic polypeptide growth factor released from platelets at the injury site. It is amultifunctional molecule that regulates DNA synthesis and cell division and induces biological effects that are implicated in tissue repair, atherosclerosis, inflammatory responses, and neoplastic diseases. This paper is an overview of the toxicology data generated from a broad testing platform to determine bone, soft tissue, and systemic responses following administration of rhPDGF-BB.Moreover, the systemic and local toxicity of recombinant human PDGF-BB (rhPDGF-BB) in combination with either beta-tricalcium phosphate (β-TCP) or collagen combined with β-TCP was studied to determine dermal sensitization, irritation, intramuscular tissue responses, pyrogenicity, genotoxicity, and hemolytic properties. All data strongly suggest that rhPDGF-BB either alone or in combination with β-TCP or collagen with β-TCP is biocompatible and has neither systemic nor local toxicity, supporting its safe use in enhancing wound healing in patients. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
19. Clinical, biochemical, mitochondrial, and metabolomic aspects of methylmalonate semialdehyde dehydrogenase deficiency: Report of a fifth case.
- Author
-
Dobrowolski, Steven F., Alodaib, Ahmad, Karunanidhi, Anuradha, Basu, Shrabini, Holecko, Meghan, Lichter-Konecki, Uta, Pappan, Kirk L., and Vockley, Jerry
- Subjects
- *
AMINO acid analysis , *ALANINE , *GASTROESOPHAGEAL reflux , *FATTY acids , *ORGANIC acids , *AMINO acids , *SUPEROXIDES - Abstract
Methylmalonate semialdehyde dehydrogenase deficiency (MMSDD; MIM 614105) is a rare autosomal recessive defect of valine and pyrimidine catabolism. Four prior MMSDD cases are published. We present a fifth case, along with functional and metabolomic analysis. The patient, born to non-consanguineous parents of East African origin, was admitted at two weeks of age for failure to thrive. She was nondysmorphic, had a normal brain MRI, and showed mild hypotonia. Gastroesophageal reflux occurred with feeding. Urine organic acid assessment identified excess 3-hydroxyisobutyrate and 3-hydroxypropionate, while urine amino acid analysis identified elevated concentrations of β-aminoisobutyrate and β-alanine. Plasma amino acids showed an elevated concentration of β-aminoisobutyrate with undetectable β-alanine. ALDH6A1 gene sequencing identified a homozygous variant of uncertain significance, c.1261C > T (p.Pro421Ser). Management with valine restriction led to reduced concentration of abnormal analytes in blood and urine, improved growth, and reduced gastroesophageal reflux. Western blotting of patient fibroblast extracts demonstrated a large reduction of methylmalonate semialdehyde dehydrogenase (MMSD) protein. Patient cells displayed compromised mitochondrial function with increased superoxide production, reduced oxygen consumption, and reduced ATP production. Metabolomic profiles from patient fibroblasts demonstrated over-representation of fatty acids and fatty acylcarnitines, presumably due to methylmalonate semialdehyde shunting to β-alanine and subsequently to malonyl-CoA with ensuing increase of fatty acid synthesis. Previously reported cases of MMSDD have shown variable clinical presentation. Our case continues the trend as clinical phenotypes diverge from prior cases. Recognition of mitochondrial dysfunction and novel metabolites in this patient provide the opportunity to assess future patients for secondary changes that may influence clinical outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
20. HEPTANOATE AND DERIVATIVES AS THERAPY FOR MCAD DEFICIENCY: PRECLINICAL EVIDENCE OF EFFICACY AND IMPLICATIONS FOR ANAPLEROTIC DRUG CLASS THERAPY.
- Author
-
Mohsen, Al-Walid, Vockley, Jerry, Karunanidhi, Anuradha, Basu, Shakuntala, Zhao, Xue-Jun, and D'Annable, Olivia
- Subjects
- *
DRUG therapy - Published
- 2022
- Full Text
- View/download PDF
21. Molecular and cellular pathology of very-long-chain acyl-CoA dehydrogenase deficiency.
- Author
-
Schiff, Manuel, Mohsen, Al-Walid, Karunanidhi, Anuradha, McCracken, Elizabeth, Yeasted, Renita, and Vockley, Jerry
- Subjects
- *
MOLECULAR pathology , *CELLULAR pathology , *ACYL-CoA dehydrogenases , *ENZYME deficiency , *IN vitro studies , *RETROSPECTIVE studies ,DIAGNOSIS of neonatal diseases - Abstract
Abstract: Background: Very-long-chain acyl-CoA dehydrogenase (VLCAD) deficiency (VLCADD) is diagnosed in the US through newborn screening (NBS). NBS often unequivocally identifies affected individuals, but a growing number of variant patterns can represent mild disease or heterozygous carriers. Aims: To evaluate the validity of standard diagnostic procedures for VLCADD by using functional in vitro tools. Methods: We retrospectively investigated 13 patient samples referred to our laboratory because of a suspicion of VLCADD but with some uncertainty to the diagnosis. All 13 patients were suspected of having VLCADD either because of abnormal NBS or suggestive clinical findings. ACADVL genomic DNA sequencing data were available for twelve of them. Ten of the patients had an abnormal NBS suggestive of VLCADD, with three samples showing equivocal results. Three exhibited suggestive clinical findings and blood acylcarnitine profile (two of them had a normal NBS and the third one was unscreened). Assay of VLCAD activity and immunoblotting or immunohistologic staining for VLCAD were performed on fibroblasts. Prokaryotic mutagenesis and expression studies were performed for nine uncharacterized ACADVL missense mutations. Results: VLCAD activity was abnormal in fibroblast cells from 9 patients (8 identified through abnormal NBS, 1 through clinical symptoms). For these 9 patients, immunoblotting/staining showed the variable presence of VLCAD; all but one had two mutated alleles. Two patients with equivocal NBS results (and a heterozygous genotype) and the two patients with normal NBS exhibited normal VLCAD activity and normal VLCAD protein on immunoblotting/staining thus ruling out VLCAD deficiency. Nine pathogenic missense mutations were characterized with prokaryotic expression studies and showed a decrease in enzyme activity and variable stability of VLCAD antigen. Conclusions: These results emphasize the importance of functional investigation of abnormal NBS or clinical testing suggestive but not diagnostic of VLCADD. A larger prospective study is necessary to better define the clinical and metabolic ramifications of the defects identified in such patients. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
22. Development and characterization of a mouse model for Acad9 deficiency.
- Author
-
Sinsheimer, Andrew, Mohsen, Al-Walid, Bloom, Kailyn, Karunanidhi, Anuradha, Bharathi, Sivakama, Wu, Yijen L., Schiff, Manuel, Wang, Yudong, Goetzman, Eric S., Ghaloul-Gonzalez, Lina, and Vockley, Jerry
- Subjects
- *
LABORATORY mice , *FATTY acid oxidation , *ANIMAL disease models , *MUSCLE weakness , *INBORN errors of metabolism , *MYOCARDIUM , *KNOCKOUT mice , *ARM circumference - Abstract
Acyl CoA Dehydrogenase 9 (ACAD9) is a member of the family of flavoenzymes that catalyze the dehydrogenation of acyl-CoAs to 2,3 enoyl-CoAs in mitochondrial fatty acid oxidation (FAO). Inborn errors of metabolism of all family members, including ACAD9, have been described in humans, and represent significant causes of morbidity and mortality particularly in children. ACAD9 deficiency leads to a combined defect in fatty acid oxidation and oxidative phosphorylation (OXPHOS) due to a dual role in the pathways. In addition to its function in mitochondrial FAO, ACAD9 has a second function as one of 14 factors responsible for assembly of complex I of the electron transport chain (ETC). Considerable controversy remains over the relative role of these two functions in normal physiology and the disparate clinical findings described in patients with ACAD9 deficiency. To better understand the normal function of ACAD9 and the pathophysiology of its deficiency, several knock out mouse models were developed. Homozygous total body knock out appeared to be lethal as no ACAD9 animals were obtained. Cre-lox technology was then used to generate tissue-specific deletion of the gene. Cardiac-specific ACAD9 deficient animals had severe neonatal cardiomyopathy and died by 17 days of age. They had severe mitochondrial dysfunction in vitro. Muscle-specific mutants were viable but exhibited muscle weakness. Additional studies of heart muscle from the cardiac specific deficient animals were used to examine the evolutionarily conserved signaling Intermediate in toll pathway (ECSIT) protein, a known binding partner of ACAD9 in the electron chain complex I assembly pathway. As expected, ECSIT levels were significantly reduced in the absence of ACAD9 protein, consistent with the demonstrated impairment of the complex I assembly. The various ACAD9 deficient animals should serve as useful models for development of novel therapeutics for this disorder. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. Characterization of variants of uncertain significance in isovaleryl-CoA dehydrogenase identified through newborn screening: An approach for faster analysis.
- Author
-
D'Annibale, Olivia M., Koppes, Erik A., Alodaib, Ahmad N., Kochersperger, Catherine, Karunanidhi, Anuradha, Mohsen, Al-Walid, and Vockley, Jerry
- Subjects
- *
NEWBORN screening , *INBORN errors of metabolism , *MUTANT proteins , *TANDEM mass spectrometry , *CIRCULATING tumor DNA , *DIAGNOSIS , *GENOME editing - Abstract
Clinical standard of care for newborn screening (NBS) is acylcarnitine metabolites quantitation by tandem mass spectrometry (MS/MS) from dried blood spots. Follow up sequencing often results in identification of one or more variants of uncertain significance (VUS). Isovaleric acidemia (IVA) is an autosomal recessive inborn error of metabolism caused by deficiency of isovaleryl-CoA dehydrogenase (IVDH) in the Leu catabolism pathway. Many IVD mutations are characterized as VUS complicating IVA clinical diagnoses and treatment. We present a testing platform approach to confirm the functional implication of VUS identified in newborns with IVA applicable to multiple inborn errors of metabolism identified by NBS. An IVD null HEK293T cell culture model was generated by using a dual sgRNA CRISPR/Cas9 genome-editing strategy targeting IVD exons 2–3. Clonal cell lines were confirmed by a combination of genomic breakpoint sequencing and droplet digital PCR. The IVD null model had no IVDH antigen signal and 96% reduction in IVDH enzyme activity. The IVD null model was transfected with vectors containing control or variant IVD and functional assays were performed to determine variant pathogenicity. c.149G > C (p.Arg50Pro; precursor numbering), c.986T > C (p.Met329Thr), and c.1010G > A (p.Arg337Gln), c.1179del394 f. mutant proteins had reduced IVDH protein and activity. c.932C > T (p.Ala311Val), c.707C > T (p.Thr236Ile), and c.1232G > A (p.Arg411Gln) had stable IVDH protein, but no enzyme activity. c.521T > G (p.Val174Gly) had normal IVDH protein and activity. IVD variant transfection results confirmed results from IVA fibroblasts containing the same variants. We have developed an IVD null HEK293T cell line to rapidly allow determination of VUS pathogenicity following identification of novel alleles by clinical sequencing following positive NBS results for suspected IVA. We suggest similar models can be generated via genome-editing for high throughput assessment of VUS function for a multitude of inborn errors of metabolism and can ideally supplement NBS programs. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Synthetic mRNA rescues very long-chain acyl-CoA dehydrogenase deficiency in patient fibroblasts and a murine model.
- Author
-
Zhao, Xue-Jun, Mohsen, AI-Walid, Mihalik, Stephanie, Solo, Keaton, Aliu, Ermal, Shi, Huifang, Basu, Shakuntala, Kochersperger, Catherine, Van't Land, Clinton, Karunanidhi, Anuradha, Coughlan, Kimberly A., Siddiqui, Summar, Rice, Lisa M., Hillier, Shawn, Guadagnin, Eleonora, Giangrande, Paloma H., Martini, Paolo G.V., and Vockley, Jerry
- Subjects
- *
ACYL coenzyme A , *GLUCOSE-6-phosphate dehydrogenase , *MESSENGER RNA , *FIBROBLASTS , *LIVER proteins , *FATTY liver - Abstract
Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency is an inborn error of long chain fatty acid β-oxidation (FAO) with limited treatment options. Patients present with heterogeneous clinical phenotypes affecting predominantly heart, liver, and skeletal muscle. While VLCAD deficiency is a systemic disease, restoration of liver FAO has the potential to improve symptoms more broadly due to increased total body ATP production and reduced accumulation of potentially toxic metabolites. We explored the use of synthetic human VLCAD (hVLCAD) mRNA and lipid nanoparticle encapsulated hVLCAD mRNA (LNP-VLCAD) to generate functional VLCAD enzyme in patient fibroblasts derived from VLCAD deficient patients, mouse embryonic fibroblasts, hepatocytes isolated from VLCAD knockout (Acadvl -/- ) mice, and Acadvl -/- mice to reverse the metabolic effects of the deficiency. Transfection of all cell types with hVLCAD mRNA resulted in high level expression of protein that localized to mitochondria with increased enzyme activity. Intravenous administration of LNP-VLCAD to Acadvl -/- mice produced a significant amount of VLCAD protein in liver, which declined over a week. Treated Acadvl -/- mice showed reduced hepatic steatosis, were more resistant to cold stress, and accumulated less toxic metabolites in blood than untreated animals. Results from this study support the potential for hVLCAD mRNA for treatment of VLCAD deficiency. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. Long-chain Acyl-CoA Dehydrogenase Deficiency as a Cause of Pulmonary Surfactant Dysfunction.
- Author
-
Goetzman, Eric S., Alcorn, John F., Bharathi, Sivakama S., Uppala, Radha, McHugh, Kevin J., Kosmider, Beata, Chen, Rimei, Zuo, Yi Y., Beck, Megan E., McKinney, Richard W., Skilling, Helen, Suhrie, Kristen R., Karunanidhi, Anuradha, Yeasted, Renita, Otsubo, Chikara, Ellis, Bryon, Tyurina, Yulia Y., Kagan, Valerian E., Mallampalli, Rama K., and Vockley, Jerry
- Subjects
- *
LUNG diseases , *SUDDEN infant death syndrome , *FATTY acid oxidation , *LECITHIN , *MITOCHONDRIA , *ACYL-CoA dehydrogenases , *LABORATORY mice , *ENERGY metabolism - Abstract
Background: The contribution of long-chain acyl-CoA dehydrogenase (LCAD) to human fatty acid oxidation is not understood. Results: LCAD localizes to lung alveolar type II cells, which produce pulmonary surfactant; LCAD-deficient mice have surfactant dysfunction. Conclusion: LCAD is important for lung energy metabolism and lung function. Significance: LCAD may play a role in human lung disease and unexplained sudden infant death. Long-chain acyl-CoA dehydrogenase (LCAD) is a mitochondrial fatty acid oxidation enzyme whose expression in humans is low or absent in organs known to utilize fatty acids for energy such as heart, muscle, and liver. This study demonstrates localization of LCAD to human alveolar type II pneumocytes, which synthesize and secrete pulmonary surfactant. The physiological role of LCAD and the fatty acid oxidation pathway in lung was subsequently studied using LCAD knock-out mice. Lung fatty acid oxidation was reduced in LCAD-/- mice. LCAD-/- mice demonstrated reduced pulmonary compliance, but histological examination of lung tissue revealed no obvious signs of inflammation or pathology. The changes in lung mechanics were found to be due to pulmonary surfactant dysfunction. Large aggregate surfactant isolated from LCAD-/- mouse lavage fluid had significantly reduced phospholipid content as well as alterations in the acyl chain composition of phosphatidylcholine and phosphatidylglycerol. LCAD-/- surfactant demonstrated functional abnormalities when subjected to dynamic compression-expansion cycling on a constrained drop surfactometer. Serum albumin, which has been shown to degrade and inactivate pulmonary surfactant, was significantly increased in LCAD-/- lavage fluid, suggesting increased epithelial permeability. Finally, we identified two cases of sudden unexplained infant death where [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
26. A multiomics approach to understanding pathology of Combined D,L-2- Hydroxyglutaric Aciduria and phenylbutyrate as potential treatment.
- Author
-
Phua YL, D'Annibale OM, Karunanidhi A, Mohsen AW, Kirmse B, Dobrowolski SF, and Vockley J
- Abstract
Combined D, L-2-Hydroxyglutaric Aciduria (D,L-2HGA) is a rare genetic disorder caused by recessive mutations in the SLC25A1 gene that encodes the mitochondrial citrate carrier protein (CIC). SLC25A1 deficiency leads to a secondary increase in mitochondrial 2-ketoglutarate that, in turn, is reduced to neurotoxic 2-hydroxyglutarate. Clinical symptoms of Combined D,L-2HGA include neonatal encephalopathy, respiratory insufficiency and often with death in infancy. No current therapies exist, although replenishing cytosolic stores by citrate supplementation to replenish cytosolic stores has been proposed. In this study, we demonstrated that patient derived fibroblasts exhibited impaired cellular bioenergetics that were worsened with citrate supplementation. We hypothesized treating patient cells with phenylbutyrate, an FDA approved pharmaceutical drug, would reduce mitochondrial 2-ketoglutarate, leading to improved cellular bioenergetics including oxygen consumption and fatty acid oxidation. Metabolomic and RNA-seq analyses demonstrated a significant decrease in intracellular 2-ketoglutarate, 2-hydroxyglutarate, and in levels of mRNA coding for citrate synthase and isocitrate dehydrogenase. Consistent with the known action of phenylbutyrate, detected levels of phenylacetylglutamine was consistent with the drug acting as 2-ketoglutarate sink in patient cells. Our pre-clinical studies suggest citrate supplementation is unlikely to be an effective treatment of the disorder. However, cellular bioenergetics suggests phenylbutyrate may have interventional utility for this rare disease.
- Published
- 2023
- Full Text
- View/download PDF
27. ITCH deficiency clinical phenotype expansion and mitochondrial dysfunction.
- Author
-
Wolfe R, Heiman P, D'Annibale O, Karunanidhi A, Powers A, Mcguire M, Seminotti B, Dobrowolski SF, Reyes-Múgica M, Torok KS, Mohsen AW, Vockley J, and Ghaloul-Gonzalez L
- Abstract
Autoimmune Disease, Multisystem, with Facial Dysmorphism (ADMFD) is an autosomal recessive disorder due to pathogenic variants in the ITCH gene. It is characterized by failure to thrive, dysmorphic facial features, developmental delay, and systemic autoimmunity that can manifest variably with autoimmune hepatitis, thyroiditis, and enteropathy, among other organ manifestations. It was originally described in 10 consanguineous Old Order Amish patients, and more recently in two patients of White British and Black German ethnicities. While the role of ITCH protein in apoptosis and inflammation has previously been characterized, a defect in cellular bioenergetics has not yet been reported in ITCH deficiency. Here we present a Caucasian female originally evaluated for possible mitochondrial respiratory chain deficiency, who ultimately was found to have two novel variants in ITCH with absence of ITCH protein in patient derived fibroblasts. Clinical studies of patient muscle showed mitochondrial DNA copy number of 57% compared to controls. Functional studies in skin fibroblasts revealed decreased activity of mitochondrial fatty acid oxidation and oxidative phosphorylation, and decreased overall ATP production. Our findings confirm mitochondrial energy dysfunction in a patient with ITCH deficiency offering the opportunity to assess alternative therapeutic options., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
28. Evaluation of mitochondrial bioenergetics, dynamics, endoplasmic reticulum-mitochondria crosstalk, and reactive oxygen species in fibroblasts from patients with complex I deficiency.
- Author
-
Leipnitz G, Mohsen AW, Karunanidhi A, Seminotti B, Roginskaya VY, Markantone DM, Grings M, Mihalik SJ, Wipf P, Van Houten B, and Vockley J
- Subjects
- Acyl-CoA Dehydrogenases deficiency, Adenosine Triphosphate agonists, Adenosine Triphosphate biosynthesis, Electron Transport drug effects, Electron Transport genetics, Electron Transport Complex I genetics, Endoplasmic Reticulum drug effects, Endoplasmic Reticulum metabolism, Endoplasmic Reticulum pathology, Fibroblasts drug effects, Fibroblasts pathology, Free Radical Scavengers pharmacology, Gene Expression, Humans, Membrane Potential, Mitochondrial drug effects, Mitochondria drug effects, Mitochondria enzymology, Mitochondria pathology, Mitochondrial Diseases enzymology, Mitochondrial Diseases pathology, NADH Dehydrogenase deficiency, Nitrogen Oxides pharmacology, Oxidative Phosphorylation drug effects, Primary Cell Culture, Reactive Oxygen Species antagonists & inhibitors, Acyl-CoA Dehydrogenases genetics, Electron Transport Complex I deficiency, Fibroblasts enzymology, Mitochondrial Diseases genetics, NADH Dehydrogenase genetics, Reactive Oxygen Species metabolism
- Abstract
Mitochondrial complex I (CI) deficiency is the most frequent cause of oxidative phosphorylation (OXPHOS) disorders in humans. In order to benchmark the effects of CI deficiency on mitochondrial bioenergetics and dynamics, respiratory chain (RC) and endoplasmic reticulum (ER)-mitochondria communication, and superoxide production, fibroblasts from patients with mutations in the ND6, NDUFV1 or ACAD9 genes were analyzed. Fatty acid metabolism, basal and maximal respiration, mitochondrial membrane potential, and ATP levels were decreased. Changes in proteins involved in mitochondrial dynamics were detected in various combinations in each cell line, while variable changes in RC components were observed. ACAD9 deficient cells exhibited an increase in RC complex subunits and DDIT3, an ER stress marker. The level of proteins involved in ER-mitochondria communication was decreased in ND6 and ACAD9 deficient cells. |ΔΨ| and cell viability were further decreased in all cell lines. These findings suggest that disruption of mitochondrial bioenergetics and dynamics, ER-mitochondria crosstalk, and increased superoxide contribute to the pathophysiology in patients with ACAD9 deficiency. Furthermore, treatment of ACAD9 deficient cells with JP4-039, a novel mitochondria-targeted reactive oxygen species, electron and radical scavenger, decreased superoxide level and increased basal and maximal respiratory rate, identifying a potential therapeutic intervention opportunity in CI deficiency.
- Published
- 2018
- Full Text
- View/download PDF
29. Preclinical Toxicology Studies of Recombinant Human Platelet-Derived Growth Factor-BB Either Alone or in Combination with Beta-Tricalcium Phosphate and Type I Collagen.
- Author
-
Young CS, Bradica G, Hart CE, Karunanidhi A, Street RM, Schutte L, and Hollinger JO
- Abstract
Human platelet-derived growth factor-BB (hPDGF-BB) is a basic polypeptide growth factor released from platelets at the injury site. It is a multifunctional molecule that regulates DNA synthesis and cell division and induces biological effects that are implicated in tissue repair, atherosclerosis, inflammatory responses, and neoplastic diseases. This paper is an overview of the toxicology data generated from a broad testing platform to determine bone, soft tissue, and systemic responses following administration of rhPDGF-BB. Moreover, the systemic and local toxicity of recombinant human PDGF-BB (rhPDGF-BB) in combination with either beta-tricalcium phosphate (β-TCP) or collagen combined with β-TCP was studied to determine dermal sensitization, irritation, intramuscular tissue responses, pyrogenicity, genotoxicity, and hemolytic properties. All data strongly suggest that rhPDGF-BB either alone or in combination with β-TCP or collagen with β-TCP is biocompatible and has neither systemic nor local toxicity, supporting its safe use in enhancing wound healing in patients.
- Published
- 2011
- Full Text
- View/download PDF
30. Cellular uptake of functional nanogels prepared by inverse miniemulsion ATRP with encapsulated proteins, carbohydrates, and gold nanoparticles.
- Author
-
Siegwart DJ, Srinivasan A, Bencherif SA, Karunanidhi A, Oh JK, Vaidya S, Jin R, Hollinger JO, and Matyjaszewski K
- Subjects
- Animals, Blotting, Western, Cell Proliferation, Cells, Cultured, Endothelium, Vascular cytology, Endothelium, Vascular metabolism, Flow Cytometry, Humans, Mesenchymal Stem Cells metabolism, Mice, Nanogels, Skull cytology, Skull metabolism, Spheroids, Cellular, Stem Cells metabolism, Tissue Distribution, Umbilical Veins cytology, Umbilical Veins metabolism, Carbohydrates chemistry, Endocytosis, Gold chemistry, Nanoparticles, Polyethylene Glycols chemistry, Polyethylene Glycols pharmacokinetics, Polyethyleneimine chemistry, Polyethyleneimine pharmacokinetics, Proteins metabolism
- Abstract
Atom transfer radical polymerization (ATRP) was used to produce a versatile drug delivery system capable of encapsulating a range of molecules. Inverse miniemulsion ATRP permitted the synthesis of biocompatible and uniformly cross-linked poly(ethylene oxide)-based nanogels entrapping gold nanoparticles, bovine serum albumin, rhodamine B isothiocyanate-dextran, or fluoresceine isothiocyanate-dextran. These moieties were entrapped to validate several biological outcomes and to model delivery of range of molecules. Cellular uptake of nanogels was verified by transmission electron microscopy, gel electrophoresis, Western blotting, confocal microscopy, and flow cytometry. Fluorescent colocalization of nanogels with a fluorophore-conjugated antibody for clathrin indicated clathrin-mediated endocytosis. Furthermore, internalization of nanogels either with or without GRGDS cell attachment-mediating peptides was quantified using flow cytometry. After 45 min of incubation, the uptake of unmodified FITC-Dx-loaded nanogels was 62%, whereas cellular uptake increased to >95% with the same concentration of GRGDS-modified FITC-Dx nanogels. In addition, a spheroidal coculture of human umbilical vascular endothelial cells (HUVECs) and human mesenchymal stem cells (hMSCs) validated cell endocytosis. Application of ATRP enabled the synthesis of a functionalized drug delivery system with a uniform network that is capable of encapsulating and delivering inorganic, organic, and biological molecules.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.